Alterations in platelet CA2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production

Diabetologia

Volumn 42, Issue 2, 1999, Pages 167-176

  Schaeffer, G ^a   Wascher, T C ^a   Kostner, G M ^a   Graier, W F ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

ADP; Ca2+ signalling; Nitric oxide; Platelet; Superoxide anions; Thapsigargin

Indexed keywords

BUTHIONINE SULFOXIMINE; HYPOXANTHINE; NITRIC OXIDE; SUPEROXIDE; XANTHINE OXIDASE; ADENOSINE DIPHOSPHATE; ANTIOXIDANT; CALCIUM; ENZYME INHIBITOR; GLUTATHIONE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; THAPSIGARGIN;

ADULT; ARTICLE; ATHEROGENESIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; VASCULAR DISEASE; BLOOD; CALCIUM SIGNALING; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ADULT; ANTIOXIDANTS; BLOOD PLATELETS; CALCIUM; CALCIUM SIGNALING; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; PLATELET AGGREGATION; SUPEROXIDES; THAPSIGARGIN;

EID: 0033069782     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051135     Document Type: Article

References (42)

1. 1. Cohen R (1993) Dysfunction of vascular endothelium in diabetes mellitus. Circulation 87 [Suppl V]:V67-V76
2. 2+-free medium. Eur J Pharmacol 256: 215-219
3. 3. Levy SB (1984) Platelets and diabetes mellitus. N Engl J Med 311: 665-667
4. 4. Bastyr EJ, Kadrofske MM, Dershimer C, Vinik AI (1989) Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM. Diabetes 38: 1097-1102
5. 5. Shukla SD, Paul A, Klachko DM (1992) Hypersensitivity of diabetic human platelets to platelet activating factor. Throm Res 66: 239-246
6. 6. van Zile J, Klipatrick M, Laimins M, Sagel J, Virella G (1981) Platelet aggregation and release of ATP after incubation with soluble immune complex purified from the serum of diabetic patients. Diabetes 30: 575-579
7. 7. Heemskerk JWM, Sage SO (1994) Calcium signalling in platelets and other cells. Platelets 5: 295-316
8. 8. Sage SO, Merritt JE, Hallam TJ, Rink TJ (1989) Receptor-mediated calcium entry in fura-2-loaded human platelets with ADP and thrombin. Biochem J 258: 923-926
9. 2+-dependent manner by zooxanthellatoxin-A, a novel polyol. Br J Pharmacol 115: 433-440
10. + transport in diabetes mellitus. Diabetes 39: 850-854
11. 2+ release from internal stores in human platelets. Br J Pharmacol 119: 1361-1366
12. 12. Trovati M, Massucco P, Mattiello L et al. (1996) The insulin-induced increase of guanosine-3,5-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes 45: 768-770
13. 13. Trovati M, Anfossi G, Massucco P et al. (1997) Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3,5-cyclic monophosphate and adenosine-3,5-cyclic monophosphate. Diabetes 46: 742-749
14. 14. Nakashima S, Tohmatsu T, Hattori H, Okano Y, Nozawa Y (1986) Inhibitory action of cGMP on secretion, phosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochem Biophys Res Commun 135:1099-1104
15. 15. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric Oxide: Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev 43: 109-142
16. 16. Rabini RA, Staffolani R, Fumelli P, Mutus B, Curatola G, Mazzanti L (1998) Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM. Diabetologia 41: 101-104
17. 17. Catella-Lawson F, FitzGerald GA (1996) Oxidative stress and platelet activation in diabetes mellitus. Diabetes Res Clin Pract 30 [Suppl]:S13-S18
18. 18. Leoncini G, Signorello MG, Piana A, Carrubba M, Armani U (1997) Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. Throm Res 86: 153-160
19. 2+/EDRF signalling is due to generation of Superoxide anions. Diabetes 45: 1386-1395
20. 20. Graier WF, Posch K, Wascher TC, Kukovetz WR, Kostner GM (1997) Role of superoxide anions in changes of endothelial vasoactive response during acute hyperglycaemia. Horm Metab Res 29: 622-629
21. 21. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton LJ (1997) The classification of diabetes by clinical and C-peptide acriteria. A prospective population-based study. Diabetes Care 20:198-201
22. 2+ entry pathways activated by the tumor promoter thapsigargin in human platelets. Biochim Biophys Acta 1220: 37-41
23. 23. Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ, Kukovetz WR (1993) Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response. Diabetes 42: 1497-1505
24. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450
25. 25. Steinbrecher UP (1988) Role of Superoxide in endothelial-cell modification of low-density lipoproteins. Biochim Biophys Acta 959: 20-30
26. 2+ signalling pathways. Arterioscler Thromb Vasc Biol 18:1470-1479
27. 27. Morley D, Maragos CM, Zhang XY, Boignon M, Wink DA, Keefer LK (1993) Mechanism of vascular relaxation induced by the nitric oxide (NO)/nucleophile complexes, a new class of NO-based vasodilators. J Cardiovasc Pharmacol 21: 670-676
28. 2+ mobilization, and protein phosphorylation in platelets from NIDDM patients. Diabetes 39: 1561-1568
29. 29. Savi P, Beauverger P, Labouret C et al. (1998) Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEES Lett 422: 291-295
30. 30. Thastrup O, Dawson AP, Scharff O et al. (1989) Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage. Agents and Actions 27:17-23
31. 31. Williamson JR, Chang K, Frangos M et al. (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813
32. 2+/cGMP response by scavenging superoxide anions. Eur J Pharmacol 322: 113-122
33. 33. Wu G, Meininger CJ (1995) Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol 269:H1312-H1318
34. 34. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF (1997) High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96:28-28
35. 35. Martina V, Bruno GA, Trucco F et al. (1998) Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 79: 520-522
36. 2+ concentration. Biochem Biophys Res Commun 215: 842-848
37. 37. Pieper GM, Siebeneich W, Dondlinger LA (1996) Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur J Pharmacol 317: 317-320
38. 38. Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM (1997) Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 40: 910-915
39. 39. Mendez JD, Zarzoza E (1997) Inhibition of platelet aggregation by L-arginine and polyamines in alloxan treated rats. Biochem Mol Biol Int 43: 311-318
40. 40. Pieper GM (1997) Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 29: 8-15
41. 41. Stroes E, Kastelein J, Cosentino F et al. (1997) Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 99: 41-46
42. 42. Wascher TC, Posch K, Wallner S, Hermetter A, Kostner GM, Graier WF (1997) Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase? Biochem Biophys Res Commun 234: 35-38